用(γ,n)反应生产放射性药物^(123)I的研究  

Feasibility study on ~123I produced by photonuclear reaction on xenon at election linac of 200MeV

作　　者：裴元吉[1] 刘清亮[1] 李裕熊[1] 陈文明[1] 许柄 罗雪芳[1] 孙葆根[1] 汪勇先[2] 盛树刚[2] 张新华[2] 曹本红[2] 王高栋 

机构地区：[1]中国科学技术大学,合肥230029 [2]中国科学院上海原子核研究所,上海201800

出　　处：《核技术》2000年第8期562-566,共5页Nuclear Techniques

基　　金：国家攀登(B)项目资助!(85-45-02-1-1)

摘　　要：从理论和实验上对光核反应生成放射性药物~１２３Ｉ进行了研究，给出了有关^(１２４)Ｘｅ（γ，ｎ）^(１２３)Ｘｅ→^(１２３)Ｉ的理论计算公式和计算结果。描述了利用合肥国家同步辐射实验室２００ＭｅＶ电子直线加速器的束流和在其末端建立的实验装置。文中给出了实验得到的反应产物的放射性活度、γ射线的谱图以及化学纯度分析结果。实验结果表明：若用纯的^(１２４)Ｘｅ进行生产，在该加速器上经两个半小时照射，将可得到１８．５ＧＢｑ以上的^(１２３)Ｉ药物。The production of 123I via photonuclear reactions has been studied both theoretically and experimentally. A facility for producing 123I by photonuclear reaction on natural xenon at an electron linac of 200MeV in National Synchrotron Radiation Laboratory, USTC was established and described in the paper. Some research results, such as the 123I yield, γ -ray spectrum of iodine isotopes, nuclear purity, and chemical purity, were given. The experimental results show that 123 I yield of 18.5GBq will be possible if average current is increased to 6 u A. a pure 124Xe (100%) target is used instead of the natural xenon and the gas target thickness reaches to 6g/cm2.

关 键 词：光核反应 放射性药物 核纯度 碘^123 生产 

分 类 号：TL921[核科学技术—核燃料循环与材料] R817.9[医药卫生—影像医学与核医学]